Please read Dr. Gélinas’ article in the Journal of Clinical and Translational Science titled, “The NJ Alliance for Clinical and Translational Science (NJ ACTS) experience: Responding at “warp speed” to COVID-19.“
The COVID-19 pandemic’s need for life-saving treatments and a “warp speed” vaccine challenged the National Institutes of Health’s Clinical and Translational Science Award (CTSA) recipients to improve their methods and processes in conducting clinical research. While CTSA recipient, New Jersey Alliance for Clinical and Translational Science (NJ ACTS), responded to this call to action with significant clinical research milestones, a comprehensive understanding of regulatory metrics during the COVID-19 pandemic is uncertain. The objective of this research is to identify, compare, and contrast metrics that illustrate the effectiveness of NJ ACTS’s research mobilization efforts during COVID-19. To read the full article.
The NJ Alliance for Clinical and Translational Science (NJ ACTS) experience: Responding at “warp speed” to COVID-19. Thaman P, Tafuto B, Gélinas C, Gaur S, Neubauer JA. J Clin Transl Sci. 2022 Apr 4;6(1):e62. eCollection 2022. PMID: 35720969 PMCID: PMC9161045 DOI: 1017/cts.2022.383